Experimental cell therapy for cervical cancer stalls after just 5 patients

NCT ID NCT05357027

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new treatment called TC-E202 for people with advanced cervical cancer that had stopped responding to standard treatments. TC-E202 uses a patient's own immune cells, which are genetically modified in a lab to better recognize and attack cancer cells. The trial was terminated early after enrolling only 5 participants, so we have very limited information about how safe or effective this approach might be.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TC-E202 cells (genetically engineered T cells targeting HPV16 E6)
What this could lead to
If successful, this approach could point toward a new treatment option for advanced cervical cancer that has not responded to standard therapies.
What could go wrong
This was a very early, small trial (only 5 participants) that was terminated early, so we have very little data on safety or effectiveness. The treatment also requires strong chemotherapy and IL-2, which can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Xiaochun Cheng

    Chongqing, Chongqing Municipality, 400000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.